Furthermore, the RPL23 expression levels of our patients presented significant variation among higher-risk MDS patients, and some patients with a higher-risk phenotype exhibited normal or lower RPL23 expression levels. This evidence concerns the gene RPL23 and myelodysplastic syndrome.